MENU
+Compare
XBI
ETF ticker: NYSE ARCA
AS OF
Oct 16, 04:58 PM (EDT)
Price
$107.82
Change
-$0.55 (-0.51%)
Net Assets
6.38B

XBI stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U... Show more

Category: #Health
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for XBI with price predictions
Oct 15, 2025

XBI in +2.74% Uptrend, growing for three consecutive days on October 09, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XBI advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for XBI just turned positive on September 18, 2025. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 221 cases where XBI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

XBI broke above its upper Bollinger Band on September 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Biotech ETF ETF is 9.88B. The market cap for tickers in the group ranges from 105.43M to 399.63B. ABBV holds the highest valuation in this group at 399.63B. The lowest valued company is SCLX at 105.43M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Biotech ETF ETF was 195%. For the same ETF, the average monthly price growth was 314%, and the average quarterly price growth was 612%. CGEM experienced the highest price growth at 34%, while SCLX experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Biotech ETF ETF was 20%. For the same stocks of the ETF, the average monthly volume growth was 69% and the average quarterly volume growth was 127%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 76
Price Growth Rating: 48
SMR Rating: 87
Profit Risk Rating: 82
Seasonality Score: 18 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com